scispace - formally typeset
H

Henri J L M Timmers

Researcher at Radboud University Nijmegen

Publications -  174
Citations -  9567

Henri J L M Timmers is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Paraganglioma & Pheochromocytoma. The author has an hindex of 44, co-authored 150 publications receiving 6955 citations. Previous affiliations of Henri J L M Timmers include University Medical Center Groningen & Radboud University Nijmegen Medical Centre.

Papers
More filters
Journal ArticleDOI

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Katherine A Hoadley, +738 more
- 05 Apr 2018 - 
TL;DR: Molecular similarities among histologically or anatomically related cancer types provide a basis for focused pan-cancer analyses, such as pan-gastrointestinal, Pan-gynecological, pan-kidney, and pan-squamous cancers, and those related by stemness features, which may inform strategies for future therapeutic development.
Journal ArticleDOI

Genomic and Functional Approaches to Understanding Cancer Aneuploidy

Alison M. Taylor, +732 more
- 09 Apr 2018 - 
TL;DR: The genomic and phenotypic correlates of cancer aneuploidy are defined and genome engineering is applied to delete 3p in lung cells, causing decreased proliferation rescued in part by chromosome 3 duplication.
Journal ArticleDOI

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

Nelly Burnichon, +60 more
TL;DR: Germline mutations in MAX are responsible for 1.12% of PCC/PGL in patients without evidence of other known mutations and should be considered in the genetic work-up of these patients.
Journal ArticleDOI

Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.

TL;DR: SDHB-related PGL often presents as apparently sporadic PGL with symptoms related to tumor mass effect rather than to catecholamine excess, whereas 10% of tumors are biochemically silent, and the clinical expression of these tumors cannot be predicted by the genotype.